Current Report Filing (8-k)
November 17 2017 - 5:00PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November
17, 2017
Creative Medical Technology Holdings,
Inc.
(Exact name of registrant as specified in
its charter)
Nevada
|
|
000-53500
|
|
87-0622284
|
(State or other jurisdiction of
incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
2017 W Peoria Avenue, Phoenix, AZ 85029
|
(Address of principal executive offices)
|
Registrant’s telephone number, including
area code:
(602) 680-7439
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
x
Emerging growth company If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
|
Item 1.01
|
Entry into a Material Definitive Agreement.
|
On November 17, 2017, Creative Medical
Technology Holdings, Inc., a Nevada corporation (the “
Company
”), entered into a Management Reimbursement Agreement
dated November 17, 2017 (the “
Agreement
”), with Creative Medical Technologies, Inc. (“
CMT
”),
the wholly owned subsidiary of the Company, and with Creative Medical Health, Inc., the parent of the Company (“
CMH
”).
The Agreement memorializes the arrangement between the parties whereby the Company has, since January 1, 2016, reimbursed CMH for
the services of management and consultants employed by CMH and performing services for the Company and CMT. The following table
sets forth the amounts of the monthly reimbursements:
Name
|
|
Reimbursement Amount
|
|
Timothy Warbington
|
|
$
|
10,000
|
|
Thomas Ichim, PhD
|
|
$
|
5,000
|
|
Donald Dickerson
|
|
$
|
10,000
|
|
Annette Marleau
|
|
$
|
5,000
|
|
Dr. Amit Patel
|
|
$
|
5,000
|
|
TOTAL
|
|
$
|
35,000
|
|
At the option of CMH, the reimbursable
amounts set forth in the Agreement may be paid from time to time in shares of common stock of the Company at a price equal to a
30% discount to the lowest closing price (as reported by OTC Markets or other principal trading platform or market for the Company’s
common stock) during the 20 trading days prior to time the notice is given. The Agreement may be terminated by either party upon
30 days’ prior written notice.
|
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
|
The information for this item is incorporated
by reference to the disclosure contained in Item 1.01 above.
|
Item 9.01.
|
Financial Statements and Exhibits
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Creative Medical Technology Holdings, Inc.
|
|
|
|
|
Date: November 17, 2017
|
By:
|
/s/ Timothy Warbington
|
|
|
Timothy Warbington, Chief Executive Officer
|